CD8A and familial pancreatic carcinoma: To assess the translational potential of these early findings, Lin et al. used IRE alone or alongside allogenic NK cell therapy in 71 patients with stage III or IV pancreatic cancer.136 IRE with NK therapy increased survival of patients with either stage III or IV disease and produced substantial increases in CD4+ and CD8+ T lymphocytes, NK cells, and B cells for stage III patients.